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Abstract: Ramelteon is a selective melatonin receptor (MT1 and MT2) agonist that has been 
approved by the US Food and Drug Administration for the treatment of insomnia characterized 
by difﬁ  culty with sleep onset. It is the only approved sleep-promoting medication that does 
not have a direct sedating effect, but rather enhances sleep through effects on sleep regulatory 
mechanisms within the suprachiasmatic nucleus. Ramelteon has been shown to have no abuse 
liability and therefore is not scheduled by the U.S. Drug Enforcement Agency as a controlled 
substance. It is available as an 8 mg tablet, which should be taken approximately 30 minutes 
prior to bedtime. The FDA approval contains no limitation on how long the medication may 
be prescribed.
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Introduction
Insomnia, the most common sleep-related complaint, is an occasional problem for 
approximately one third of the general population. Ten to 15% of adults suffer with 
chronic insomnia. The prevalence is higher among elderly individuals and in people 
with comorbid medical and psychiatric disorders. Chronic insomnia is associated 
with impaired daytime functioning, decreased quality of life, and increased health 
care utilization.
Insomnia sufferers seek relief with a remarkable array of substances, including alco-
hol, herbal and homeopathic preparations, dietary supplements, and over-the-counter 
antihistamines. Health care providers may recommend an assortment of sedating 
psychotropic medications as primary treatments for insomnia. Among these are anti-
depressants (eg, trazodone, doxepin), antipsychotics (eg, quetiapine), anticonvulsants 
(eg, gabapentin, tiagabine), and higher-dose antihistamines (eg, diphenhydramine). 
Convincing evidence is lacking for the efﬁ  cacy in the treatment of chronic insomnia 
of all of the above compounds (National Institutes of Health 2005). Additionally, there 
are signiﬁ  cant safety concerns associated with each of these approaches.
In June 2005, a US National Institutes of Health (NIH)-sponsored panel reviewed 
the published evidence regarding the treatment of chronic insomnia (National Insti-
tutes of Health 2005). The panel concluded that evidence supports only cognitive 
behavioral therapy and the US Food and Drug Administration (FDA)-approved 
benzodiazepine receptor agonist (BZRA) hypnotic medications. At the time of this 
panel statement, ramelteon had not yet been approved, and little efﬁ  cacy data were 
available for review.
For several decades the BZRA hypnotic medications were the only medications 
approved by the FDA for the treatment of insomnia. Initially, all of the BZRAs struc-
turally were benzodiazepines. In the early 1990s, non-benzodiazepine BZRAs became 
available and ultimately became the most widely prescribed hypnotics. However, many 
new pharmacologic agents with novel mechanisms of action have been investigated Neuropsychiatric Disease and Treatment 2008:4(1) 70
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as possible sleep-promoting agents. Ramelteon is the ﬁ  rst of 
these new mechanism of action sleep-promoting medications 
to be approved by the FDA.
Sleep-wake cycle regulation
Normally the timing of sleep and wakefulness are strongly 
inﬂ  uenced by the combined effects of homeostatic and 
circadian processes (Richardson 2005). In humans, the 
homeostatic system promotes sleep for about one third of 
the time, or a total of approximately 8 hours daily. Sleepi-
ness builds up during waking and is dissipated during sleep. 
Insufﬁ  cient sleep leads to increased sleepiness. Following 
nighttime sleep, there is a steady buildup of sleepiness from 
the homeostatic process throughout the day and evening 
until one falls asleep at nighttime again. People generally 
do not subjectively experience the increasing homeostatic 
sleep pressure due to the opposing alerting signal from the 
circadian system, which is promoting maximum arousal 
during the evening. The late afternoon and evening circadian 
arousal, coordinated by activity in the suprachiasmatic nuclei, 
provides the ability for people to remain awake and active 
for approximately 16 hours. While the homeostatic system 
promotes the amount of sleep people need, the circadian 
system optimizes when that sleep best can be achieved. The 
quality and duration of both wakefulness and sleep may be 
impaired when the homeostatic and circadian systems are 
dissociated, as can occur with jet lag and shift work.
The production and release of melatonin by the pineal 
gland ultimately is regulated by the suprachiasmatic nucleus 
(SCN) (Turek and Gillette 2004). Typically melatonin is 
produced and the level rises in the evening as one’s usual 
bedtime is approaching. The melatonin level plateaus during 
the night and declines later during the night as the end of the 
normal sleep period approaches. There are two melatonin 
receptor subtypes in the SCN. Agonists of the MT1 receptor 
subtype decrease the evening alerting signal and therefore 
enhance sleep onset. The MT2 receptor subtype serves to 
reinforce or shift the timing of the circadian system. Under 
normal circumstances, the dual agonist activity promotes 
sleep onset directly and also reinforces the regular timing of 
evening sleepiness and sleep onset.
Ramelteon history
In 1992 Takeda initiated a plan to research alternate strate-
gies to address the treatment of insomnia. They focused on 
creating a melatonin receptor agonist. In 1996 TAK-375, 
now known as ramelteon, was developed. Clinical trials of 
the compound began in 1999. These trials have included 
over 7900 unique subjects and over 800 subject-years of 
use. The studies conducted in the development of ramelteon 
have included general efﬁ  cacy and safety protocols, as well 
as speciﬁ  c studies examining pharmacokinetic and pharma-
codynamic characteristics, toxicology, abuse liability, and 
use in special populations. The New Drug Application for 
ramelteon was submitted to the FDA in September 2004, 
and was approved in July 2005. Ramelteon became avail-
able for use in the US in September 2005, under the brand 
name Rozerem.
Chemistry
Ramelteon ((S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]
furan-8-yl)ethyl]propionamide) is the single (S)-enantiomer 
of a tricyclic indan derivative. The structure of ramelteon is 
shown in Figure 1.
Pharmacokinetics
Ramelteon is rapidly absorbed and reaches a peak serum 
concentration in less than one hour (Hibberd and Stevenson 
2004; Karim et al 2006a). There is extensive first-pass 
metabolism, and the mean systemic availability following an 
oral dose is less than 2% (Amakye et al 2004). In humans, 
protein binding is approximately 82% (Takeda Pharmaceu-
ticals North America 2006). Pharmacokinetic studies of 
ramelteon at a wide range of doses show a large degree of 
intersubject variability in the peak concentration and total 
systemic exposure (Karim et al 2006). Administration of 
ramelteon with food increases the AUC, delays the Tmax, and 
decreases the Cmax (Karim et al 2004a). The onset of action 
should be faster on an empty stomach; however, this may not 
Table 1 Ramelteon: key characteristics
Brand name  Rozerem
FDA spproval  July 2005
DEA dtatus  Unscheduled
Indication  For the treatment of insomnia 
 characterizedby  difﬁ  culty with sleep
 onset
Mechanism of action  Selective melatonin receptor agonist
Peak concentration time  45 minutes
(median)
Elimination half-life  1–2.6 hours
(approximate)
Available doses  8 mg
Prescribing recommendation  8 mg 30 minutes prior to bedtime
Warnings  Moderate to severe hepatic impairment
 Coadministration  with  ﬂ  uvoxamine
Adverse events  Somnolence (5%)
 Dizziness  (5%)
 Fatigue  (4%)Neuropsychiatric Disease and Treatment 2008:4(1) 71
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be clinically signiﬁ  cant. The use of ramelteon with or soon 
after a high-fat meal is not recommended due to the expected 
delay in absorption.
The metabolism of ramelteon is primarily through the 
CYP1A2 isozyme and secondarily through the CYP2C 
subfamily and CYP3A4 isozymes. The elimination half-life 
for ramelteon generally is under 2 hours in adults and elderly 
subjects, and is not inﬂ  uenced by gender (Karim et al 2006; 
Greenblatt et al 2007). Serum measurements in humans 
identify four metabolites: M-I, M-II, M-III, and M-IV. The 
only active metabolite is M-II, which has similar pharma-
codynamic properties with about one-tenth the potency of 
ramelteon. The M-II metabolite has the greatest systemic 
exposure, but has an elimination half-life of approximately 
2–4 hours (Karim et al 2006).
Pharmacodynamics
In vitro receptor binding assays have shown that ramelteon is 
an agonist of the MT1 and MT2 melatonin receptor subtypes 
(Kato et al 2005). In comparison with melatonin, ramelteon 
had signiﬁ  cantly greater afﬁ  nity and selectivity for these 
binding sites. The dissociation constant (Ki) of ramelteon in 
the in vitro studies was 3–16 times higher than melatonin. 
In contrast with melatonin, ramelteon had signiﬁ  cantly 
lower afﬁ  nity for the MT3 binding site, which represents a 
melatonin-sensitive form of the enzyme quinone reductase 2 
that has wide tissue distribution in mammals. In vitro studies 
also have demonstrated that ramelteon has no measurable 
afﬁ  nity for a large number of tested ligand binding sites, 
including benzodiazepine, dopamine, and opiate receptors.
Preclinical animal studies to assess sleep-related effects 
have been conducted with freely moving cats (Miyamoto et al 
2004) and macaque monkeys (Yukuhiro et al 2004). In the 
cat study, orally administered ramelteon was compared with 
exogenous melatonin. Monitoring for sleep characteristics 
included the electroencephalogram, muscle tension, and eye 
movements. Ramelteon signiﬁ  cantly reduced wakefulness 
over a wide dosage range with effects lasting up to 6 hours, 
in contrast to the effects of exogenous melatonin lasting up 
to 2 hours. Furthermore, ramelteon was found to be about 10 
times more potent than melatonin in promoting sleep.
The study with macaques compared the effects of oral 
doses of ramelteon, exogenous melatonin, and zolpidem 
(Yukuhiro et al 2004). Ramelteon demonstrated signiﬁ  cantly 
shortened sleep onset latency and increased total duration of 
sleep, while melatonin had a weaker effect on sleep latency 
and no effect on sleep duration. No behavior changes were 
present with ramelteon and melatonin; however, zolpidem 
at the highest dose was associated with sedation and muscle 
relaxation.
Efﬁ  cacy for transient insomnia
Two studies have investigated the effects of ramelteon com-
pared with placebo in a model of transient insomnia in healthy 
subjects without sleep complaints. Both have taken advantage 
of the “ﬁ  rst night effect” in a sleep laboratory, when the abil-
ity to fall asleep and remain asleep may be challenged in this 
novel sleep environment. In one clinical trial, 375 subjects 
were given ramelteon 16 or 64 mg, or placebo (Roth et al 
2005). The polysomnographic recording demonstrated a 
signiﬁ  cantly shorter latency to persistent sleep and increased 
total sleep time with both ramelteon doses. The similar sleep 
latencies found with both doses suggests a ﬂ  at dose-response 
curve. The second transient insomnia model study involved 
289 healthy subjects who were given ramelteon 8 mg, 16 mg, 
or placebo (Zammit et al 2005). The polysomnographic 
recording showed that the subjects taking both doses of the 
ramelteon fell asleep faster and slept longer to a signiﬁ  cant 
degree in comparison with the placebo group. The latency to 
persistent sleep for the ramelteon 8 mg and placebo subjects 
H5C2CONHCH2CH2 H
O
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were 12.2 and 19.7 minutes, respectively. The total sleep time 
for the ramelteon 8 mg and placebo groups were 436.8 and 
419.7 minutes, respectively.
Efﬁ  cacy for chronic insomnia
The efﬁ  cacy of ramelteon in promoting statistically signiﬁ  -
cant reductions in latency to persistent sleep and increases in 
total sleep time across a broad dosage range in chronic insom-
nia subjects was demonstrated in a double-blind, placebo-
controlled, ﬁ  ve-period crossover study of 107 adult subjects 
(ages 18–64 years) (Erman et al 2006). Each of the subjects 
followed a randomized dosing sequence that included two 
treatment nights with a placebo and ramelteon 4, 8, 16, and 
32 mg. The similar polysomnographically determined sleep 
latency values over this range of ramelteon dosages suggests 
a ﬂ  at dose-response curve. There were no differences among 
the ramelteon doses and placebo with regard to wake time 
after sleep onset.
A 5-week, double-blind study of 405 adults (ages 18–64 
years) with chronic insomnia incorporated both objective poly-
somnographic and patient-reported measures (Zammit et al 
2007). The subjects were randomized to groups with nightly 
doses of ramelteon 8 mg or 16 mg, or placebo. The 35 treat-
ment nights were preceded by a 1-week single-blind placebo 
baseline period and were followed by a single-blind 2-night 
placebo run-out to assess potential withdrawal or rebound 
(sleep characteristics worse than study baseline values) effects. 
Sleep laboratory efﬁ  cacy assessments were performed for 2 
nights during weeks 1, 3, and 5. Compared with the placebo 
group, both ramelteon doses resulted in signiﬁ  cantly shorter 
polysomnographically recorded sleep latency values through-
out the treatment period. The patient-reported sleep latencies 
also were signiﬁ  cantly shorter than the placebo at weeks 1, 3, 
and 5 for the 8 mg dose (Figure 2) and at weeks 1 and 3 for 
the 16 mg dose. Polysomnographically determined total sleep 
time and sleep efﬁ  ciency were statistically greater than placebo 
for both ramelteon doses at week 1. During subsequent weeks 
statistical signiﬁ  cance with greater total sleep time and sleep 
efﬁ  ciency was found only at the 16 mg dose during week 3. The 
patient-reported total sleep time was signiﬁ  cantly greater for 
the 8 mg dose during weeks 1, 3, and 5, and for the 16 mg dose 
during week 1. There was no evidence of rebound insomnia or 
withdrawal effects on single-blind placebo run-out discontinu-
ation at either ramelteon dose.
One hundred elderly chronic insomnia subjects (mean 
age 70.7 years) participated in a three-way crossover study 
involving ramelteon 4 mg and 8 mg and placebo (Roth et al 
2007). Both polysomnographically recorded sleep latency 
and total sleep time were signiﬁ  cantly better in the ramelteon 
4 mg and 8 mg groups compared with the placebo group; 
however, the subjective total sleep time measures did not 
reach statistical signiﬁ  cance. There was a signiﬁ  cant reduc-
tion in the subjective sleep latency in the 4 mg group.
The efﬁ  cacy of ramelteon was assessed in 829 older adult 
(ages 64–93 years) chronic insomnia subjects enrolled in a 
5-week outpatient trial with groups receiving nightly doses 
of ramelteon 4 mg, 8 mg, or placebo (Roth et al 2006). 
One-week single-blind placebo periods occurred before 
and after the double-blind treatment period. Compared with 
the placebo group, the sleep diary outcomes demonstrated 
signiﬁ  cantly shorter subjective sleep onset latencies for both 
ramelteon dose groups at week 1 and week 5, and for the 
8 mg group at all three assessments. The 8 mg group was not 
signiﬁ  cantly different from the placebo group for reported 
total sleep time, although the 4 mg group was signiﬁ  cant for 
the week 1 and 3 assessments. However, the overall treatment 
effect combining the two ramelteon treatment groups also 
resulted in signiﬁ  cantly better total sleep time relative to the 
placebo group at weeks 1 and 3. There were no signiﬁ  cant 
differences between ramelteon and placebo regarding sleep 
quality, number of nighttime awakenings, and ease of falling 
back to sleep. With discontinuation, there was no evidence 
of rebound insomnia or withdrawal effects.
A subset including 327 of the above 829 older adults met 
a criterion for severe sleep initiation difﬁ  culty with reported 
baselines equal to or greater than 60 minutes (Mini et al 
2007). In this subanalysis, 157 subjects had been randomized 
to the ramelteon 8 mg group and 170 to the placebo group. 
Statistically signiﬁ  cant improvement from baseline remained 
signiﬁ  cantly better in the ramelteon group compared with 
the placebo group at weeks 1 through 5. By week 1 the mean 
reported sleep latency decreased by 7.5 minutes in the placebo 
group and 23.2 minutes in the ramelteon group. At week 5 the 
improvement relative to baseline for the placebo group was 
17.1 minutes and for the ramelteon group was 37.4 minutes.
The long-term nightly use of ramelteon was evaluated in 
a 12-month open-label, non-placebo-controlled outpatient 
study of 1213 adult and elderly subjects meeting criteria for 
chronic insomnia (DeMicco et al 2006). The adults (ages 
18–64 years) were given ramelteon 16 mg, and the elderly 
subjects (ages 65 and older) were given 8 mg. At 6 months, 
597 subjects remained in the study, and 473 subjects com-
pleted the full 12 months (Richardson et al 2006a). Sleep 
diary data showed that in comparison with baseline sleep 
latency estimates, both elderly and adult subjects experienced 
improvement at month 1 (34.0% and 35.1%, respectively), Neuropsychiatric Disease and Treatment 2008:4(1) 73
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month 6 (44.7% and 49.1%), and month 12 (50.3% and 
52.1%) (DeMicco et al 2006). Total sleep time estimates also 
showed steady improvement for elderly and adult subjects at 
month 1 (15.2% and 16.9%), month 6 (21.6% and 22.7%), 
and month 12 (25.5% and 23.9%). Clinical Global Impres-
sion assessments also reﬂ  ected the moderate and sustained 
improvement. A single-blind 3-day placebo run-out at the 
end of the study showed no signiﬁ  cant prolongation in sleep 
latency that would reﬂ  ect rebound insomnia.
The longest assessment of both objective and subjective 
measures in a placebo-controlled study with the nightly use 
of a pharmacologic agent in the treatment of chronic insomnia 
subjects has been reported with a 6-month ramelteon clinical 
trial (Wang-Weigand et al 2007). A total of 451 adults with 
chronic insomnia were randomized to ramelteon 8 mg or 
placebo groups. Two consecutive nights of polysomnographic 
recording were completed at week 1 and months 1, 3, 5, and 
6 of treatment, and week 1 of a single-blind placebo run-
out. Subjective sleep variables were measured with morning 
questionnaires. Relative to placebo, the ramelteon subjects 
experienced statistically significantly shorter objective 
latency to persistent sleep throughout the 6-month study. 
Subjective sleep latency also was shorter throughout the study 
and reached statistical signiﬁ  cance at week 1, month 1, and 
month 5. There was no evidence of withdrawal or rebound 
insomnia on discontinuation.
Efﬁ  cacy in facilitating circadian 
phase shifts
Although human studies examining the efﬁ  cacy of ramelteon 
in the treatment of circadian rhythm disorders have not been 
presented, preliminary investigations suggest possible future 
applications in this clinical area. In a study with rats, the 
animals were entrained to a 12-hour light-dark cycle and then 
subjected to an abrupt 8-hour advance phase shift. The ability 
of ramelteon or melatonin to facilitate the phase shift in rat 
activity rhythm was compared with a vehicle control during 
14 days of administration at the same time of day (Hirai 
et al 2005). The primary outcome measure was the number 
of days required for the animals to exhibit at least 85% of 
typical activity during the night for 2 consecutive days. Both 
ramelteon and melatonin accelerated the reentrainment to the 
new light-dark cycle following the abrupt phase shift.
The phase-shifting effects in healthy human subjects were 
examined in a study of 18 subjects during a 4-period cross-
over study including ramelteon 4 mg and 16 mg, melatonin 
5 mg, and placebo (Richardson et al 2005). The ramelteon 
doses were effective in producing a phase advance of the 
endogenous circadian rhythm as indicated by the timing of 
the evening dim light salivary melatonin onset.
In a subsequent trial, a 5-hour phase advance was imposed 
on 75 healthy adults who were randomized to receive ramelt-
eon 1 mg, 2 mg, 4 mg, 8 mg, or placebo. The subjects were 
conﬁ  ned in a sleep laboratory under low-intensity light for 
ﬁ  ve nights and six days. Ramelteon 1 mg, 2 mg, and 4 mg 
produced a signiﬁ  cantly greater and more rapid circadian 
phase advance compared with placebo (−80.9 min, p = 0.002; 
−73.3 min, p = 0.003; and 83.4 min, p = 0.001, respectively), 
as indicated by endogenous melatonin secretion offset time; 
the 8 mg dose showed a phase advance that did not reach 
statistical signiﬁ  cance (−27.9 min, p = 0.392) (Richardson 
et al 2006b).
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Figure 2 Ramelteon efﬁ  cacy: Subject-reported sleep latency in adults with chronic insomnia during a 5-week double-blind, placebo-controlled study (derived from data of 
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Safety and tolerability
The safety of ramelteon has been examined in numerous 
preclinical and clinical trials. The efﬁ  cacy trials have 
demonstrated a lack of signiﬁ  cant next-morning residual 
sedation and cognitive impairment using questionnaires 
and measures, such as the digit symbol substitution test 
and the visual analog scale for alertness. Speciﬁ  c safety 
studies have focused on potential interactions with ethanol 
and selected coadministered medications, as well as abuse 
liability, endocrine effects, and use in special medical 
populations. There is no evidence of discontinuation with-
drawal symptoms. Ramelteon and placebo subjects had 
similar scores on the Tyrer Benzodiazepine Withdrawal 
Symptom Questionnaire (Takeda Pharmaceuticals North 
America 2006). Figure 3 shows the incidence of treatment-
emergent adverse events in the clinical studies (Takeda 
Pharmaceuticals North America 2006). The adverse 
event items that were reported by at least 2% more of the 
ramelteon subjects compared with placebo subjects during 
the clinical trials included only somnolence (5% vs 3%), 
dizziness (5% vs 3%), and fatigue (4% vs 2%).
A broad range of safety parameters were monitored 
during the one-year, open-label, non-placebo-controlled 
study of ramelteon 16 mg (adults) and 8 mg (older adults) 
noted above (DeMicco et al 2006; Richardson et al 2006a). 
No clinically meaningful changes were reported regarding 
vital signs, physical exams, clinical chemistry, hematol-
ogy, urinalysis, and electrocardiogram trends. No notable 
endocrine or sexual/reproductive function changes were 
observed except for a slight decrease in the free and total 
testosterone levels in older males on selected monthly visits. 
The testosterone levels returned to the normal range by the 
ﬁ  nal visit of the study.
The absence of balance difﬁ  culty due to ramelteon has 
been conﬁ  rmed in three studies. In each report the effects 
of the medication were no different from placebo, while 
subjects given active comparators demonstrated evidence 
of acute impairment in balance. A total of 260 adult chronic 
insomnia subjects completed a protocol involving 14 nightly 
doses of placebo, ramelteon 8 mg, or zopiclone 7.5 mg. On 
the last night the subjects slept in a laboratory setting and 
were awakened 1.5–2 hours following the evening dose. The 
subjects stood on a balance platform and were assessed for 
sway. The ramelteon subjects were the same as the placebo 
group; however, the zopiclone group had a signiﬁ  cantly worse 
calculated area of center of pressure on the platform (Hajak 
et al 2007). Thirty-three older adult chronic insomnia subjects 
participated in a single-dose crossover study examining the 
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effects of placebo, ramelteon 8 mg, and zolpidem 10 mg on 
balance. Two hours following a bedtime dose, the subjects 
were awakened and assessed for balance and mobility with 
computerized dynamic posturography. Only on the zolpidem 
nights did the subjects exhibit signiﬁ  cant impairment rela-
tive to the placebo performance (Wang-Weigand et al 2007). 
Balance was among the outcomes investigated in an abuse 
liability crossover study of substance abusers given daytime 
ramelteon (16–160 mg), triazolam (0.25–0.75 mg), and 
placebo doses. The effects of ramelteon on balance were no 
different from placebo throughout the wide dose range; how-
ever, balance impairment was noted at the higher triazolam 
doses (Johnson et al 2006).
Pharmacokinetic interaction studies
Pharmacokinetic studies have examined the possible effects 
of ramelteon coadministered with commonly prescribed 
medications or those that are representative of hepatic iso-
zyme inhibitors or inducers. Overall, ramelteon was shown 
not to have a signiﬁ  cant effect on the serum concentration 
of coadministered medications. In some cases there were 
statistically signiﬁ  cant increases or decreases in the ramelteon 
level due to the hepatic isozyme inhibition or induction of 
the coadministered medication. Medications tested that had 
no signiﬁ  cant effect on the systemic exposure of ramelteon 
included dextromethorphan (Tolbert et al 2004a), digoxin 
(Tolbert et al 2004b), midazolam (Karim et al 2004b), zolpi-
dem (Karim et al 2007a), and warfarin (Karim et al 2005b). 
The systemic exposure of ramelteon was decreased by 
rifampin (Karim et al 2004c) (potent CYP inducer) and ser-
traline (Karim et al 2006c) and was increased by theophylline 
(Tolbert et al 2004c) (CYP1A2 substrate), ﬂ  uoxetine (Sainati 
et al 2004) (CYP2D6 inhibitor), escitalopram (Karim et al 
2006b), donepezil (Karim et al 2007b), omeprazole (Karim 
et al 2005a), venlafaxine (Karim et al 2006d), ﬂ  uconazole 
(Karim et al 2004d) (CYP2C9 inhibitor), and ketoconazole 
(Karim et al 2004d) (CYP3A4 inhibitor). Coadministration 
of ramelteon and ethanol resulted in a 50% increase in the 
exposure of ramelteon (Karim et al 2004e).
Even with moderate changes in the ramelteon levels from 
coadministered medications, these interactions generally have 
not been regarded as clinically signiﬁ  cant for the following 
reasons. Ramelteon undergoes extensive ﬁ  rst-pass metabo-
lism, has highly variable plasma concentrations and a wide 
therapeutic window, and has a ﬂ  at dose-effect relationship. 
That it is metabolized by several hepatic isoenzymes also 
limits the potential for drug interactions. The one medication 
that may markedly elevate the ramelteon concentration is the 
potent CYP1A2 isozyme inhibitor, ﬂ  uvoxamine (Luvox), 
and therefore combined use is not recommended (Takeda 
Pharmaceuticals North America 2006).
Special population safety studies
The safety of ramelteon in patients with mild-to-moderate 
COPD was examined in a double-blind, placebo-controlled, 
two-way crossover study of 26 subjects (Sainati et al 2005; 
Kryger et al 2008). The oxygen saturation for each hour and 
for the entire night was comparable between the ramelteon 16 
mg and placebo, suggesting no respiratory depressant effects 
in these subjects. The mean oxygen saturation values for 
ramelteon 16 mg and placebo nights during non-REM sleep 
were 92.9 and 92.7, and during REM sleep the values were 
92.5 and 92.1, respectively. A similarly designed study of 26 
mild-to-moderate obstructive sleep apnea subjects (apnea-
hypopnea index (AHI) range 5 through 20) given ramelteon 
16 mg and placebo on different nights showed no exacerba-
tion of the sleep-disordered breathing (AHI 11.4 and 11.1, 
respectively) (Kryger et al 2007). Oxygen saturation through-
out the night and during speciﬁ  c sleep stages was similar for 
the placebo and ramelteon 16 mg nights, except for a slight 
increase during REM sleep for the ramelteon night.
Patients with mild, moderate, and severe renal impair-
ment, including subjects treated with dialysis, were studied 
following single and multiple doses of ramelteon 16 mg 
(Tolbert et al 2004d). There was no correlation between the 
degree of renal impairment and the systemic exposure of 
ramelteon. Therefore, no ramelteon dosage adjustment is 
recommended in patients with renal impairment.
The potential for hepatic disease to increase the systemic 
exposure to ramelteon was demonstrated in a study of patients 
with mild and moderate hepatic impairment in comparison 
with healthy matched control subjects following administra-
tion of single and multiple doses of ramelteon 16 mg (Karim 
et al 2004f). Caution is advised in using ramelteon in patients 
with moderate hepatic impairment, and ramelteon use is not 
recommended in patients with severe impairment (Takeda 
Pharmaceuticals North America 2006).
Potential endocrine rffects
The effects of ramelteon on endocrine function in humans 
initially was evaluated in a randomized study of 99 healthy 
subjects given nightly doses of ramelteon 16 mg or pla-
cebo for 28 days (Tolbert et al 2004e). Relative to baseline 
values, there were no signiﬁ  cant changes in any of the 12 
thyroid, reproductive, and adrenal endocrine parameters 
measured.Neuropsychiatric Disease and Treatment 2008:4(1) 76
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Potential endocrine effects of longer-term nightly use of 
ramelteon 16 mg were investigated in a placebo-controlled, 
6-month study of 122 chronic insomnia subjects (Richardson 
et al 2006c). Among the 12 parameters evaluated, there 
were no signiﬁ  cant changes in the thyroid and adrenal axes. 
Gonadotropins and testosterone were unchanged. Relative 
to baseline, there was an elevation of the mean serum pro-
lactin level observed only in women. The mean prolactin 
values remained in the normal reference range and the effect 
appeared to be transient. There were no apparent associated 
physical changes. The placebo and ramelteon groups had 
similar subject-reported menstrual patterns.
As noted above, selected endocrine parameters were 
monitored during the one-year open-label study of nightly 
ramelteon in chronic insomnia subjects (Richardson et al 
2006a). The mean endocrine values and changes from base-
line, as well as the distribution of values around the mean, 
were contained within the normal range for all parameters. 
On at least one monthly visit, adults (16 mg) and older adults 
(8 mg) demonstrated values outside the normal range for total 
testosterone (7.3% and 6.9%) and free testosterone (6.0% 
and 13.3%). There was no placebo comparison to evaluate a 
potential medication effect.
Abuse liability
Preclinical ramelteon abuse liability studies with rhesus 
monkeys demonstrated that it does not produce benzodiaz-
epine agonist-like discriminative stimulus effects in normal 
or diazepam-dependent animals (France et al 2006), does not 
cause signiﬁ  cant effects on spontaneous or learned behaviors 
when given daily and then discontinued (France et al 2006), 
and has no positive reinforcing effects in intravenous self-
administration experiments (Nishida et al 2005). Together 
these suggest an absence of physical dependence and abuse 
liability.
The human abuse liability of ramelteon has been inves-
tigated in terms of the likelihood of it being misused and 
also the liability associated with potential acute impairment 
in psychomotor and cognitive functioning (Grifﬁ  th and 
Johnson 2005). Subjects with known sedative drug abuse 
history participated in a double blind, crossover study of the 
acute effects (balance, psychomotor, and cognitive tasks) 
and drug likeability of ramelteon (16, 80, 160 mg) in com-
parison with the active control triazolam (0.25, 0.5, 0.75 mg) 
(Johnson et al 2006). With ramelteon administration up to 
20 times the recommended therapeutic dose there was no 
differentiation from placebo in any of the behavioral and 
cognitive performance measures, subjective effect responses, 
or observer-rated measures. These data conﬁ  rm the absence 
of human abuse liability with ramelteon.
Comments
Ramelteon is the first FDA-approved sleep-promoting 
medication with a unique mechanism of action that has been 
released in over 30 years. It is a melatonin receptor agonist, 
but is different from exogenous melatonin in its structure, 
receptor subtype selectivity, binding afﬁ  nity, elimination 
half-life, metabolism, and efﬁ  cacy. Moreover, exogenous 
melatonin is unregulated, while the FDA approval process 
has required an extensive evaluation of the safety and efﬁ  cacy 
of ramelteon.
Ramelteon also is readily differentiated from the BZRA 
hypnotics, which represent all of the other medications 
approved for the treatment of insomnia. Ramelteon is 
unscheduled by the Drug Enforcement Agency (DEA), 
while the BZRA hypnotics all are schedule IV controlled 
substances. It has been shown to have no abuse potential, 
tolerance, rebound insomnia on discontinuation, and no 
psychomotor or cognitive impairment. Ramelteon promotes 
sleep through its agonist activity at the MT1 and MT2 mela-
tonin receptor subtypes and thereby attenuates the normal 
evening SCN arousal signal and reinforces the phase of 
the circadian system. These actions should shorten sleep 
latency and increase the likelihood of sleepiness occurring 
at approximately the same time each night.
The patient experience with ramelteon also may be signif-
icantly different from the BZRA hypnotics, which act through 
a sedating effect. This type of medication-induced sedation 
clusters with potential adverse effects, including cognitive 
and psychomotor impairments which are not experienced 
with ramelteon. With the BZRA hypnotics, patients often are 
aware of the sedation prior to sleep onset and the maximum 
beneﬁ  t in enhancing sleep onset and maintenance typically 
is achieved with the initial dose. Depending on the elimina-
tion half-life and whether a controlled-release formulation is 
taken, BZRA hypnotics should shorten sleep onset and may 
improve sleep maintenance. In contrast, ramelteon does not 
promote sedation. Rather, it shortens sleep onset latency and 
may help maintain sleep during the early part of the night by 
attenuating the SCN arousal activity. The ramelteon clinical 
trials demonstrated both objective and subjective efﬁ  cacy in 
shortening sleep onset relative to placebo on the ﬁ  rst night the 
medication was taken. However, patients prescribed ramelt-
eon may notice the absence of the sedating effect and may not 
report optimum improvement until they have been taking the 
medication nightly for several days or weeks. There may be Neuropsychiatric Disease and Treatment 2008:4(1) 77
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a clinical analogy with antidepressant medications, although 
the reason for a subjective sense of improvement may be dif-
ferent. For some patients, the MT2 agonist effect with a shift 
to an earlier phase and a stabilization of the circadian system 
may account for this pattern of improvement.
The mechanism of action suggests that ramelteon will 
be most helpful in enhancing sleep onset when taken in the 
evening as one’s bedtime is approaching. The ramelteon pre-
scribing guidelines suggest that it be taken 30 minutes prior 
to bedtime. The bedtime sleep-promoting effect presumably 
is dependent on the attenuation of the SCN-generated arousal 
that is maximal in the evening. While BZRA hypnotics should 
have a sedating inﬂ  uence and may facilitate sleep onset at any 
hour, the pharmacodynamic effects of ramelteon may limit 
the sleep-promoting efﬁ  cacy to the evening and early night-
time hours. However, further clinical studies will be necessary 
to establish the sleep-promoting effects of ramelteon at other 
times throughout the 24-hour cycle.
The FDA-approved indication for ramelteon is for the 
treatment of insomnia characterized by difﬁ  culty with sleep 
onset. The mechanism of action explains the timing of the 
sleep-promoting effect. While there may be an increase in 
total sleep time, there is not necessarily an improvement 
in sleep maintenance. As is the case with the two BZRA 
hypnotic medications approved by the FDA in 2005, eszopi-
clone and controlled-release zolpidem, the ramelteon indi-
cation does not incorporate short-term treatment wording. 
Accordingly, in appropriate clinical situations, the approved 
ramelteon prescribing guidelines suggest that it may be used 
for an extended period.
Several features should contribute to the interest in this 
new sleep-promoting medication. These include the absence 
of abuse potential, nonscheduled DEA status, lack of cogni-
tive and psychomotor impairment, minimal potential for drug 
interactions, and the novel mechanism of action. The safety 
and efﬁ  cacy of ramelteon have been demonstrated in both 
adult and elderly subjects. Limitations include the primary 
efﬁ  cacy being sleep onset without an improvement in sleep 
maintenance.
While the current approved ramelteon indication is for 
the treatment of insomnia, the pharmacodynamic charac-
teristics raise the question of possible efﬁ  cacy for circa-
dian rhythm disorders and other clinical conditions where 
stabilization of the sleep-wake cycle would be especially 
beneﬁ  cial. The latter might include bipolar disorder and 
dementia syndromes. Preliminary studies demonstrating 
the circadian phase-shifting effects of ramelteon are noted 
above. Patients with the circadian rhythm disorder delayed 
sleep phase syndrome (DSPS) have persistent difﬁ  culty 
with sleep onset; however, they also have marked difﬁ  -
culty awakening at a desired time the following morning. 
While ramelteon would be expected to aid the sleep onset, 
the circadian phase-response relationship of exogenous 
melatonin and the preliminary ramelteon evidence suggest 
that it might have a unique role in the treatment of DSPS. 
In theory, the agonist activity at the MT1 receptor subtype 
would directly enhance sleep onset. The effect on the MT2 
receptor subtype would promote an advance in the circa-
dian system to allow an earlier sleep onset and an ability 
to awaken more readily the following morning. Ramelteon 
also might be beneﬁ  cial for the free-running non-24-hour 
rhythm blind individuals who are unable to entrain to the 
natural 24-hour photoperiod. Other potential applications 
would include helping individuals with jet lag adjust more 
rapidly to the new photoperiod of their destination and shift 
workers readapt to nighttime sleep following a schedule 
requiring sleep during the daytime.
Summary
Ramelteon is a selective melatonin receptor agonist approved 
by the FDA for the treatment of insomnia characterized by 
difﬁ  culty with sleep onset. It is unique among approved 
sleep-promoting medications due to the mechanism of action 
targeting the activity in the suprachiasmatic nucleus, as well 
as an absence of sedating effects and abuse liability.
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